Registry for Breast Cancer Patients Receiving Adjuvant Hormone Blockade Tracking Bone Mineral Metabolism and Fracture Occurrence Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna

What this Trial Is About

Researchers are establishing a registry to include all patients treated with adjuvant hormone blockade for previous breast cancer. The goal is to study the trends in bone mass and how they relate to calcium metabolism markers, as well as the occurrence and frequency of fractures over time. This registry will support future studies focused on bone health in this patient population. Patients treated with adjuvant hormone blockade, such as aromatase inhibitors, GnRH analogs, or tamoxifen, for breast cancer will be enrolled in the registry. Inclusion is offered consecutively to patients diagnosed and evaluated at the Endocrinology Unit for Bone Mineral Metabolism, in coordination with Oncology referrals. The registry includes patients seen from January 1, 2015, with enrollment ending December 31, 2029. Follow-up for each patient may last up to 10 years, with registry updates continuing through December 31, 2039. Participants will have undergone bone density scans and blood tests related to mineral metabolism. Researchers will collect and monitor data on bone mass, calcium metabolism laboratory values, and fracture incidence throughout the study period, averaging 15 years. The long-term follow-up aims to provide valuable insights into bone health outcomes in breast cancer patients receiving hormone-blocking therapies.

Registry of Adjuvant Hormone-blockade Breast Cancer Patients Evaluated for Bone Mineral Metabolism